Vertex Researchers Report First Demonstration of Tumor Growth Suppression and Regression In Vivo with Aurora Kinase Inhibitors
Study Published in Nature Medicine
24-Feb-2004
CAMBRIDGE, Mass. In Nature
medicine, researchers from Vertex Pharmaceuticals Incorporated have demonstrated for the first time that a selective small molecule inhibitor
of the Aurora kinases, VX-680, profoundly reduces tumor growth in cancer
models. Aurora kinases are known to be overexpressed in many tumor types,
including colon cancer, breast cancer, and leukemia.
Research into the function and activity of Aurora kinases over the past
several years has suggested that they may play multiple roles in the
development and progression of cancer, by acting as regulators of cell
proliferation, by transforming normal cells into cancer cells, and by
downregulating p53, one of the body's natural tumor suppressors.
In the study reported today, the small molecule Aurora kinase inhibitor
VX-680 blocked cancer cell proliferation, and also triggered cell death in a
broad range of tumor cell types. Data from in vivo xenograft models indicated
that VX-680 achieved complete inhibition of tumor growth at well-tolerated
doses, and in some instances, tumor regression was observed. The report
suggests that Aurora kinase inhibition provides a promising, novel approach
for the treatment of multiple human malignancies.
"Aurora kinases represent a potentially important class of targets for the
future treatment of cancer, and we have now demonstrated for the first time
that a small molecule Aurora kinase inhibitor not only blocks tumor cell
proliferation but also induces tumor cell death," commented Karen Miller,
Ph.D., Director of biology, Vertex Europe and senior author of the study.
"The ability of VX-680 to cause tumor regression is particularly exciting."
"VX-680 has demonstrated promising results in a range of tumor types,"
said Peter Mueller, Ph.D., Chief Scientific Officer of Vertex. "Inhibition of
Aurora kinases represents a novel and highly targeted approach to cancer
therapy, and we look forward to the evaluation of Aurora kinase inhibitors in
the clinic in 2004."
Aurora kinases (also known as BTAK and STK15) are a family of serine-
threonine kinases that have been strongly linked to tumorigenesis. Aurora
kinases, which play a central role in controlling cell division, are
disregulated in many types of human cancer, including leukemia, colon and
breast cancer. Overexpression of Aurora kinase has been shown to promote the
transformation of normal cells into cancer cells, and decreased Aurora kinase
activity is associated with enhanced function of the body's normal tumor
suppressor genes. Amplification of Aurora genes is associated with
progression of colorectal cancer and poor prognosis in certain types of breast
cancer.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
